Is Moderna Stock a No-Brainer Buy on the Sell-Off?

A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday. This update wasn't well-received by investors, and Moderna's share price sank nearly 17%.The conventional investing wisdom is that you shouldn't "try to catch a falling knife." Moderna's stock chart certainly looks like a falling knife. Even before the latest decline, the biotech stock was down roughly 73% since early June 2024. But is Moderna stock instead a no-brainer buy on the sell-off?Let's first look at why investors were so unhappy with Moderna's business update. The company generated product sales of between $3 billion and $3.1 billion in 2024. That total is less than half of the $6.67 billion in net product sales reported in 2023, and is on the low end of Moderna's previous guidance range. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool